Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43


β3-Adrenoceptor activation upregulates apolipoprotein A-I expression in HepG2 cells, which might further promote cholesterol efflux from macrophage foam cells.

Gao XQ, Li YF, Jiang ZL.

Drug Des Devel Ther. 2017 Mar 3;11:617-627. doi: 10.2147/DDDT.S130088. eCollection 2017.


Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo.

Yang Y, Rosales C, Gillard BK, Gotto AM Jr, Pownall HJ.

Biochim Biophys Acta. 2016 Nov;1861(11):1787-1795. doi: 10.1016/j.bbalip.2016.08.017. Epub 2016 Sep 2.


Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies.

Andrews J, Puri R, Kataoka Y, Nicholls SJ, Psaltis PJ.

Cardiovasc Diagn Ther. 2016 Aug;6(4):282-303. doi: 10.21037/cdt.2015.10.02. Review.


Cholesteryl Ester Transfer Protein (CETP) expression does not affect glucose homeostasis and insulin secretion: studies in human CETP transgenic mice.

Raposo HF, Vanzela EC, Berti JA, Oliveira HC.

Lipids Health Dis. 2016 Jan 13;15:9. doi: 10.1186/s12944-016-0179-6.


New Insights into the High-Density Lipoprotein Dilemma.

Pownall HJ, Gotto AM Jr.

Trends Endocrinol Metab. 2016 Jan;27(1):44-53. doi: 10.1016/j.tem.2015.11.004. Epub 2015 Dec 7. Review.


High-Density Lipoprotein Processing and Premature Cardiovascular Disease.

Rosales C, Gillard BK, Gotto AM Jr, Pownall HJ.

Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):181-5. doi: 10.14797/mdcj-11-3-181. Review.


Mechanisms of Atherosclerosis: New Insights and Novel Therapeutic Approaches.

Cooke JP.

Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):154-5. doi: 10.14797/mdcj-11-3-154. No abstract available.


Using hiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms.

Flaherty EK, Brennand KJ.

Brain Res. 2017 Jan 15;1655:283-293. doi: 10.1016/j.brainres.2015.11.009. Epub 2015 Nov 12. Review.


Analysis of "On/Off" Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics.

Lu J, Cleary Y, Maugeais C, Kiu Weber CI, Mazer NA.

CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):465-73. doi: 10.1002/psp4.27. Epub 2015 Apr 20.


Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein.

Thompson CF, Ali A, Quraishi N, Lu Z, Hammond ML, Sinclair PJ, Anderson MS, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD.

ACS Med Chem Lett. 2011 Mar 24;2(6):424-7. doi: 10.1021/ml100309n. eCollection 2011 Jun 9.


Plaque regression and plaque stabilisation in cardiovascular diseases.

Dave T, Ezhilan J, Vasnawala H, Somani V.

Indian J Endocrinol Metab. 2013 Nov;17(6):983-9. doi: 10.4103/2230-8210.122604.


High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease.

Akinkuolie AO, Paynter NP, Padmanabhan L, Mora S.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):55-63. doi: 10.1161/CIRCOUTCOMES.113.000675. Epub 2013 Nov 18.


Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Mohammadpour AH, Akhlaghi F.

Clin Pharmacokinet. 2013 Aug;52(8):615-26. doi: 10.1007/s40262-013-0071-8.


HDL and cholesterol: life after the divorce?

Vickers KC, Remaley AT.

J Lipid Res. 2014 Jan;55(1):4-12. doi: 10.1194/jlr.R035964. Epub 2013 Mar 19. Review.


Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Goldberg AS, Hegele RA.

Drug Des Devel Ther. 2012;6:251-9. doi: 10.2147/DDDT.S34976. Epub 2012 Sep 24. Review.


Mechanistic systems modeling to guide drug discovery and development.

Schmidt BJ, Papin JA, Musante CJ.

Drug Discov Today. 2013 Feb;18(3-4):116-27. doi: 10.1016/j.drudis.2012.09.003. Epub 2012 Sep 19. Review.


Crystal structures of cholesteryl ester transfer protein in complex with inhibitors.

Liu S, Mistry A, Reynolds JM, Lloyd DB, Griffor MC, Perry DA, Ruggeri RB, Clark RW, Qiu X.

J Biol Chem. 2012 Oct 26;287(44):37321-9. doi: 10.1074/jbc.M112.380063. Epub 2012 Sep 7.


Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L.

Circulation. 2012 Apr 17;125(15):1905-19. doi: 10.1161/CIRCULATIONAHA.111.066589. Review. No abstract available.


Supplemental Content

Support Center